Agents for attention-deficit hyperactivity disorder - an update

被引:5
作者
Howard, HR [1 ]
机构
[1] Pfizer Inc, PGRD Groton Labs, CNS Discovery Chem, Groton, CT 06340 USA
关键词
attention-deficit hyperactivity disorder (ADHD); dopamine; histamine; nicotine; serotonin; stimulants;
D O I
10.1517/13543776.14.7.983
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Attention-deficit hyperactivity disorder (ADHD) is a psychological disorder affecting children and adolescents, whose symptoms often persist into the adult years, and is often effectively treated with stimulants. Recently, non-stimulant medications that demonstrate better toleration and administration have been studied in clinical settings and some have been approved. Yet, there continues to be strong emphasis in many research groups to find even more efficacious and safer alternatives, especially with substances that function through novel, non-stimulatory mechanisms. A review of the progress achieved during the last 4 years, determined from the publication of patents and patent applications, is presented.
引用
收藏
页码:983 / 1008
页数:26
相关论文
共 301 条
  • [11] AM HOME PRODUCTS COR, 2002, Patent No. 02051837
  • [12] Andrews M. D., 2002, Eur. Pat. Appl., Patent No. [EP 1184372 A1, 1184372]
  • [13] [Anonymous], 1994, Diagnostic and Statistical Manual of Mental Disorders
  • [14] APODACA R, 2002, Patent No. 0212190
  • [15] APODACA R, 2002, Patent No. 0224695
  • [16] APODACA R, 2002, Patent No. 00212214
  • [17] ASLANIAN RG, 2002, Patent No. 0232893
  • [18] ASTRAZENECA AB, 2003, Patent No. 03087103
  • [19] ASTRAZENECA AB, 2001, Patent No. 0132619
  • [20] ASTRAZENECA AB, 2003, Patent No. 03087104